Technology transfer of behavioral economic tasks for assessing alcohol reinforcer pathology: Development and feasibility of a commercially-available tool for clinical practice

用于评估酒精强化病理学的行为经济任务的技术转让：用于临床实践的商用工具的开发和可行性

• 批准号: 10490351
• 负责人: Sarah Emily Snider
• 金额: $ 85.34万
• 依托单位: BEAM DIAGNOSTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-20 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10490351
• 关键词: Adoption; Alcohol consumption; Alcohols; American; Benchmarking; COVID-19 pandemic; Caring; Cause of Death; Censuses; Characteristics; Clinic; Clinical; Clinical Research; Clinical assessments; Computerized Medical Record; Data; Data Set; Decision Making; Development; Diagnostic; Distress; Education; Ensure; Environment; Feedback; Goals; Guidelines; Health Insurance Portability and Accountability Act; Healthcare; Healthcare Systems; Impairment; Individual; Internet; Language; Literature; Manuals; Measurement; Measures; Medical; Modeling; Modification; Morbidity - disease rate; Outpatients; Output; Pathology; Patients; Phase; Play; Prevalence; Process; Provider; Psychiatry; Public Health; Reporting; Rewards; Risk; Role; Sampling; Screening procedure; Secure; Security; Site; Small Business Innovation Research Grant; Small Business Technology Transfer Research; Standardization; Stigmatization; System; Tablets; Technology Transfer; Testing; Translating; Translations; United States; Validation; acceptability and feasibility; alcohol misuse; alcohol reinforcement; alcohol screening; alcohol use disorder; base; behavioral economics; clinical application; clinical development; clinical practice; combat; digital; disability; discounting; disorder risk; drinking behavior; experience; health care disparity; implementation outcomes; improved; mortality; preventable death; prototype; reinforcer; routine practice; rural area; screening; tool; usability; web app

PROJECT SUMMARY Alcohol use disorder (AUD) contributes to excessive disability, morbidity, and mortality in the United States. As one of the nation’s leading causes of death, public health guidelines recommend consistent standardized alcohol screening. However, screening for alcohol misuse is underperformed, laborious, and is susceptible to demand characteristics and concerns about stigmatizing the patient. To combat these issues, BEAM Diagnostics, Inc. developed Beacon, a commercializable alcohol misuse digital screening tool based on the theoretical framework of reinforcer pathology dedicated to increasing standardized screening without stigmatizing the patient. In Phase I of this project, we conducted a clinical study at a large multi-site healthcare system serving approximately 1M patients per year and validated Beacon as demonstrating robust predictive accuracy of alcohol misuse and positive reports of feasibility and acceptability from providers. The goal of this Phase II SBIR is to finalize Beacon’s development into a fully realized commercial product, both as a stand-alone tool and as an integrated tool within an electronic medical record (EMR) system. Aim 1 will iterate and optimize the user-experience and accessibility of Beacon as a product, develop nationally representative norming, produce comprehensive clinical reference materials, ensure offline capability, and Spanish-language translation. Aim 2 will be dedicated to integrating Beacon into EPIC, a widely used electronic medical record system within a healthsystem partner, to improve usability, workflow capabilities, and record-keeping of alcohol misuse directly into a patient’s medical chart. In addition, Aim 2 will launch a wave-style education and implementation initiative to promote Beacon’s use in three outpatient departments. Finally, BEAM will complete an Exploratory Aim seeking to validate Beacon as a measurement-based care tool. At the conclusion of this Phase II project, BEAM will brought Beacon to market as a digital screening app for AUD, both as a stand-alone product and an EMR-integrated version.

项目总结 在美国，酒精使用障碍(AUD)导致过度残疾、发病率和死亡率。AS 作为美国主要的死亡原因之一，公共卫生指南建议始终如一地标准化酒精 放映。然而，酒精滥用的筛查工作做得不好，费力，而且容易受到需求的影响。 对患者进行污名处理的特点和担忧。为了解决这些问题，BEAM诊断公司。 基于理论框架开发了可商业化的酒精滥用数字筛查工具Beacon 致力于增加标准化筛查而不使患者蒙受耻辱。同相 在这个项目中，我们在一个大型的多站点医疗保健系统中进行了一项临床研究，为大约100万人提供服务 每年的患者和经过验证的Beacon证明了酒精滥用和 供应商对可行性和可接受性的积极报告。此阶段SBIR的目标是最终确定 Beacon发展成为完全实现的商业产品，既作为独立工具，也作为集成工具 电子病历(EMR)系统中的工具。目标1将迭代和优化用户体验，并 Beacon作为产品可及性，发展全国代表性规范，生产全面临床 参考资料，确保离线能力，以及西班牙语翻译。Aim 2将致力于 将Beacon集成到EPIC中，EPIC是HealthSystem合作伙伴中广泛使用的电子医疗记录系统，以 提高可用性、工作流程功能，并将酒精滥用直接记录到患者的医疗记录中 图表。此外，Aim 2将推出波浪式教育和实施倡议，以促进Beacon的 在三个门诊部使用。最后，BEAM将完成一项探索性目标，寻求验证Beacon 作为一种基于测量的护理工具。在这个第二阶段项目结束时，BEAM将把Beacon带到 市场作为澳元的数字筛选应用程序，既作为独立产品，也作为EMR集成版本。